Current Landscape and Evolving Therapies for Primary Biliary Cholangitis
Cells · 2024
DOI: 10.3390/cells13181580 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, 2024. Verfasst von Stefano Fiorucci und 4 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Medicina e Chirurgia, Università di Perugia, 06123 Perugia, Italy. Hauptthemen laut MEDLINE: Liver Cirrhosis, Biliary. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 191 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MUR - Ministero dell'Università e della Ricerca, Italian Ministry of University and Research (MUR).
Abstract (Originalsprache)
Primary Biliary Cholangitis (PBC) is a chronic autoimmune liver disorder characterized by progressive cholestatic that, if untreated, can progress to liver fibrosis, cirrhosis and liver decompensation requiring liver transplant. Although the pathogenesis of the disease is multifactorial, there is a consensus that individuals with a genetic predisposition develop the disease in the presence of specific environmental triggers. A dysbiosis of intestinal microbiota is increasingly considered among the potential pathogenic factors. Cholangiocytes, the epithelial cells lining the bile ducts, are the main target of a dysregulated immune response, and cholangiocytes senescence has been recognized as a driving mechanism, leading to impaired bile duct function, in disease progression. Bile acids are also recognized as playing an important role, both in disease development and therapy. Thus, while bile acid-based therapies, specifically ursodeoxycholic acid and obeticholic acid, have been the cornerstone of therapy in PBC, novel therapeutic approaches have been developed in recent years. In this review, we will examine published and ongoing clinical trials in PBC, including the recently approved peroxisome-proliferator-activated receptor (PPAR) agonist, elafibranor and seladelpar. These novel second-line therapies are expected to improve therapy in PBC and the development of personalized approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dipartimento di Medicina e Chirurgia, Università di Perugia, 06123 Perugia, Italy.
- SC di Gastroenterologia ed Epatologia, Azienda Ospedaliera di Perugia, 06123 Perugia, Italy.
ORCID-Profile: Stefano Fiorucci, Michele Biagioli
Förderung
- MUR - Ministero dell'Università e della Ricerca
- Italian Ministry of University and Research (MUR)
Zitieren
APA
Fiorucci, S., Urbani, G., Di Giorgio, C., Biagioli, M., & Distrutti, E. (2024). Current Landscape and Evolving Therapies for Primary Biliary Cholangitis. Cells. https://doi.org/10.3390/cells13181580
Vancouver
Fiorucci S, Urbani G, Di Giorgio C, Biagioli M, Distrutti E. Current Landscape and Evolving Therapies for Primary Biliary Cholangitis. Cells. 2024. doi:10.3390/cells13181580
BibTeX
@article{Fiorucci2024,
author = {Fiorucci, Stefano and Urbani, Ginevra and Di Giorgio, Cristina and Biagioli, Michele and Distrutti, Eleonora},
title = {Current Landscape and Evolving Therapies for Primary Biliary Cholangitis},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13181580}
}
EUVIMED